Japan's Digital Diabetes Solutions to See Significant Growth by 2033
Tokyo, Monday, 13 October 2025.
Japan’s digital therapeutics market for diabetes is projected to grow at a 10.4% CAGR, reaching $136.44 million by 2033, driven by rising diabetes rates and innovative digital health strategies.
Integration of Technology in Diabetes Management
The integration of digital therapeutics within Japan’s healthcare system is set to redefine diabetes management. Digital therapeutics, which include software-driven medical interventions like mobile applications, wearable devices, and telehealth platforms, offer personalized treatment plans that enhance patient engagement and outcomes. By 2025, this market is expected to expand substantially, driven by the growing prevalence of diabetes and the aging population in Japan, where nearly 29% of the population is aged 65 or older [1].
Market Dynamics and Key Players
The Japan Digital Therapeutics for Diabetes Market, valued at approximately US$ 56.59 million in 2024, is projected to grow to US$ 136.44 million by 2033, reflecting a 10.4% CAGR. Major players such as Omada Health and Dexcom are pivotal in this expansion. In July 2025, Omada Health launched a new program integrating AI-driven lifestyle coaching, while Dexcom received FDA approval for its G7 continuous glucose monitoring device, which features a 15-day wear period [1].
Government Support and Regulatory Advances
The Japanese government has been proactive in supporting digital health innovations. As of April 2025, five digital therapeutics products had been approved, with two covered by national health insurance. This regulatory progress, coupled with reimbursement policies, encourages the adoption of digital therapeutics as cost-effective alternatives to traditional diabetes management methods [1].
Future Prospects and Global Alignment
Japan’s advancements in digital health are part of a global trend toward integrating technology in healthcare. The strategic partnership between Abbott and Dexcom, announced in September 2025, aims to co-develop next-generation diabetes management devices, underscoring the global shift towards digital and value-based care models [1]. The rise of AI-driven personalization in digital therapeutics, combined with wearable devices for continuous glucose monitoring, is expected to further support remote and elderly patient care [1].